Samsung Bioepis Company Profile: Valuation, Investors, Acquisition | PitchBook
Samsung Bioepis Brings Heat to Race for Anti-VEGF Biosimilars | Ophthalmology Innovation Source
Biogen of US might reap W2tr from Samsung Bioepis call option
Samsung Biologics and Biogen Idec to form Samsung Bioepis
Samsung Biologics completes full acquisition of Samsung Bioepis | World Pharma Today
Samsung Bioepis gets nod for sale of biosimilar drug in Europe | Yonhap News Agency
o9 to supply AI-powered IBP platform to Samsung Bioepis
Innovations in Biosimilars: Insights and Trends from Samsung Bioepis - Xtalks
PharmaBoardroom - Samsung Bioepis
Samsung Bioepis launches Ontruzant in Brazil
Samsung Biologics Completes Purchase Of Samsung Bioepis | Contract Pharma
Merck to develop biosimilars with Samsung-Biogen joint venture - PMLiVE
Samsung Bioepis on LinkedIn: #immunology #biosimilar #sbla #1nn0vatingaccess #pass10nforhealth
Samsung Bioepis races rivals as EMA accepts Herceptin biosim app | Fierce Biotech
Samsung Bioepis enters US market for biosimilars of Humira - KED Global
Samsung Bioepis' Biologics License Application for SB5 Adalimumab Biosimilar Candidate Accepted for Review by the U.S. Food and Drug Administration | Business Wire
Amgen withdraws patent suit against Samsung Bioepis
Samsung Bioepis launches ARMD biosimilar drug in Germany, Canada - KED Global
Samsung Bioepis' Ranibizumab Biosimilar Application Filed With FDA
Samsung Biologics to acquire Biogen's stake in Samsung Bioepis
Samsung Bioepis Racks Up More Awards for Its Biosimilar Packaging
Samsung on Samsung: Bioepis selects Biologics as a biosimilars CMO
Samsung Bioepis claims No.1 in European adalimumab biosimilar mkt - Pulse by Maeil Business News Korea
